explore -WSS

explore

author：focus 2025-09-28 00:25:47 - browse：1252

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
Next article： Pushing for an NIH office for post

focus

WSS

Steward Health Care Massachusetts hospitals face fiscal disaster

Gene editing the human germline: What are the risks?

HHS secretary Becerra pressed on Change HealthCare cyberattack

Gene editing the human germline: What are the risks?

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Intermittent fasting comes with a heart risk? Not so fast

hotspot

explore

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

John Green on his newest strategy for fighting tuberculosis

Drug repurposing or repositioning? The language matters

Readout Newsletter: Bristol, Sangamo, Gilead, and more

23andMe had bad news about my health. I wish a person had delivered it

Why depression after traumatic brain injury is distinct

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

As AI in medicine takes off, can 'human in the loop' prevent harm?

United colonoscopy coverage change 'may cost lives,' doctors say

5 to watch: Tech startups trying to solve health care's staffing crisis

explore

Virtual Event: March of the Biosimilars

John Green on his newest strategy for fighting tuberculosis

UCLA team creates talking throat patch for voice disorders

RaDonda Vaught links Vanderbilt hospital issues to patient death

Methadone treatment changes are coming. Do they go far enough?

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

focus

Wikipedia

focus

Wikipedia